Q-omics provides the consensus-scored CAVIN1 profile across patient tissues and cancer cell-line models. CAVIN1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CAVIN1 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, CAVIN1 protein abundance shows 35,752 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, BLCA, and PDAC as cancer lineages where CAVIN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAVIN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAVIN1 survival associations across molecular data types. CAVIN1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAVIN1 RNA expression–survival associations across cancer types. High CAVIN1 expression shows unfavorable associations in MESO, HNSC, BLCA and LGG, but favorable associations in UVM and ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CAVIN1 RNA expression.
This table summarizes CAVIN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CAVIN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAVIN1 shows lower tumor expression in BLCA, LUAD and KICH and higher tumor expression in HNSC, KIRC and LIHC. The BLCA box plot shows higher CAVIN1 RNA expression in normal versus tumor tissue (log2 FC = −3.167, t-test p < 0.001).
This table shows molecular features associated with CAVIN1 in patient tissues and cancer cell lines. In patient samples, CAVIN1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CAVIN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
